Integrins in tumor angiogenesis and lymphangiogenesis

Methods in Molecular Biology

Volumn 757, Issue , 2011, Pages 471-486

  Foubert, Philippe ^a   Varner, Judith A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Adhesion; Angiogenesis; Cancer; Immunohistochemistry; Integrins; Lymphangiogenesis; Migration

Indexed keywords

BIOLOGICAL MARKER; INTEGRIN;

ANIMAL; ARTICLE; BIOASSAY; CELL ADHESION; CELL MOTION; CYTOLOGY; ENDOTHELIUM CELL; HUMAN; LYMPHANGIOGENESIS; METABOLISM; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; UMBILICAL VEIN;

ANIMALS; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; CELL ADHESION; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; INTEGRINS; LYMPHANGIOGENESIS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; UMBILICAL VEINS;

EID: 80054773965     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-166-6_27     Document Type: Article

References (44)

1. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature 438, 932-936. (Pubitemid 43093958)
2. Conway, E. M., Collen, D., and Carmeliet, P. (2001) Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49, 507-521. (Pubitemid 32146414)
3. Alitalo, K., Tammela, T., and Petrova, T. V. (2005) Lymphangiogenesis in development and human disease. Nature 438, 946-953. (Pubitemid 43093960)
4. Mandriota, S. J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D. G., Orci, L., Alitalo, K., Christofori, G., and Pepper, M. S. (2001) Vascular endothelial growth factor- C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20, 672-682. (Pubitemid 32167632)
5. He, Y., Kozaki, K., Karpanen, T., Koshikawa, K., Yla-Herttuala, S., Takahashi, T., and Alitalo, K. (2002) Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94, 819-825. (Pubitemid 34705053)
6. Okazaki, T., Ni, A., Ayeni, O. A., Baluk, P., Yao, L. C., Vossmeyer, D., Zischinsky, G., Zahn, G., Knolle, J., Christner, C., and McDonald, D. M. (2009) alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation. Am. J. Pathol. 174, 2378-2387.
7. Hynes, R. O. (2002) Integrins: Bidirectional, allosteric signaling machines. Cell 110, 673-687. (Pubitemid 35283958)
8. Cheresh, D. A., and Stupack, D. G. (2008) Regulation of angiogenesis: Apoptotic cues from the ECM. Oncogene 27, 6285-6298.
9. Hynes, R. O. (2002) A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918-921. (Pubitemid 35033683)
10. Serini, G., Valdembri, D., and Bussolino, F. (2006) Integrins and angiogenesis: A sticky business. Exp. Cell Res. 312, 651-658. (Pubitemid 43290341)
11. Sund, M., Hamano, Y., Sugimoto, H., Sudhakar, A., Soubasakos, M., Yerramalla, U., Benjamin, L. E., Lawler, J., Kieran, M., Shah, A., and Kalluri, R. (2005) Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc. Natl. Acad. Sci. USA. 102, 2934-2939. (Pubitemid 40299894)
12. Senger, D. R., Claffey, K. P., Benes, J. E., Perruzzi, C. A., Sergiou, A. P., and Detmar, M. (1997) Angiogenesis promoted by vascular endothelial growth factor: Regulation through alpha1beta1 and alpha2beta1 integrins. Proc. Natl. Acad. Sci. USA. 94, 13612-13617.
13. Pozzi, A., Moberg, P. E., Miles, L. A., Wagner, S., Soloway, P., and Gardner, H. A. (2000) Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. USA. 97, 2202-2207. (Pubitemid 30134046)
14. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresh, D. A. (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270, 1500-1502. (Pubitemid 3005294)
15. Reynolds, L. E., Wyder, L., Lively, J. C., Taverna, D., Robinson, S. D., Huang, X., Sheppard, D., Hynes, R. O., and Hodivala- Dilke, K. M. (2002) Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8, 27-34. (Pubitemid 34101725)
16. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., and Cheresh, D. A. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
17. Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M., and Cheresh, D. A. (2001) Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol. 155, 459-470. (Pubitemid 34289336)
18. Reynolds, A. R., Reynolds, L. E., Nagel, T. E., Lively, J. C., Robinson, S. D., Hicklin, D. J., Bodary, S. C., and Hodivala-Dilke, K. M. (2004) Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3- integrin-deficient mice. Cancer Res. 64, 8643-8650. (Pubitemid 39552078)
19. Mahabeleshwar, G. H., Feng, W., Phillips, D. R., and Byzova, T. V. (2006) Integrin signaling is critical for pathological angiogenesis. J. Exp Med. 203, 2495-2507. (Pubitemid 44664619)
20. van Hinsbergh, V. W., Engelse, M. A., and Quax, P. H. (2006) Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb. Vasc. Biol. 26, 716-728. (Pubitemid 43732143)
21. Nikolopoulos, S. N., Blaikie, P., Yoshioka, T., Guo, W., and Giancotti, F. G. (2004) Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 6, 471-483. (Pubitemid 39469983)
22. Silva, R., D'Amico, G., Hodivala-Dilke, K. M., and Reynolds, L. E. (2008) Integrins: The keys to unlocking angiogenesis. Arterioscler. Thromb. Vasc. Biol. 28, 1703-1713.
23. Huang, X. Z., Wu, J. F., Ferrando, R., Lee, J. H., Wang, Y. L., Farese, R. V., Jr., and Sheppard, D. (2000) Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol. Cell. Biol. 20, 5208-5215. (Pubitemid 30431573)
24. Mishima, K., Watabe, T., Saito, A., Yoshimatsu, Y., Imaizumi, N., Masui, S., Hirashima, M., Morisada, T., Oike, Y., Araie, M., Niwa, H., Kubo, H., Suda, T., and Miyazono, K. (2007) Prox1 induces lymphatic endothelial differentiation via integrin alpha9 and other signaling cascades. Mol. Biol. Cell 18, 1421-1429. (Pubitemid 46626636)
25. Vlahakis, N. E., Young, B. A., Atakilit, A., Hawkridge, A. E., Issaka, R. B., Boudreau, N., and Sheppard, D. (2007) Integrin alpha9beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-Ainduced angiogenesis. J. Biol. Chem. 282, 15187-15196. (Pubitemid 47093385)
26. Hong, Y. K., Lange-Asschenfeldt, B., Velasco, P., Hirakawa, S., Kunstfeld, R., Brown, L. F., Bohlen, P., Senger, D. R., and Detmar, M. (2004) VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 18, 1111-1113. (Pubitemid 39561540)
27. Norgall, S., Papoutsi, M., Rossler, J., Schweigerer, L., Wilting, J., and Weich, H. A. (2007) Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. BMC Cancer 7, 105.
28. Zhang, X., Groopman, J. E., and Wang, J. F. (2005) Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1. J. Cell Physiol. 202, 205-214. (Pubitemid 39603377)
29. Dietrich, T., Onderka, J., Bock, F., Kruse, F. E., Vossmeyer, D., Stragies, R., Zahn, G., and Cursiefen, C. (2007) Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am. J. Pathol. 171, 361-372. (Pubitemid 47339252)
30. Sudhakar, A., Sugimoto, H., Yang, C., Lively, J., Zeisberg, M., and Kalluri, R. (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA. 100, 4766-4771. (Pubitemid 36457804)
31. Brideau, G., Makinen, M. J., Elamaa, H., Tu, H., Nilsson, G., Alitalo, K., Pihlajaniemi, T., and Heljasvaara, R. (2007) Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res. 67, 11528-11535.
32. Garmy-Susini, B., Makale, M., Fuster, M., and Varner, J. A. (2007) Methods to study lymphatic vessel integrins. Methods Enzymol 426, 415-438.
33. Friedlander, M., Theesfeld, C. L., Sugita, M., Fruttiger, M., Thomas, M. A., Chang, S., and Cheresh, D. A. (1996) Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA. 93, 9764-9769. (Pubitemid 26296683)
34. Zhang, D., Pier, T., McNeel, D. G., Wilding, G., and Friedl, A. (2007) Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. Invest. New Drugs 25, 49-55. (Pubitemid 44657642)
35. Trikha, M., Zhou, Z., Nemeth, J. A., Chen, Q., Sharp, C., Emmell, E., Giles-Komar, J., and Nakada, M. T. (2004) CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 110, 326-335. (Pubitemid 38649882)
36. Mullamitha, S. A., Ton, N. C., Parker, G. J., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K., Cheung, S., Hope, L., Valle, J. W., Radford, J. A., Lawrance, J., Saunders, M. P., Munteanu, M. C., Nakada, M. T., Nemeth, J. A., Davis, H. M., Jiao, Q., Prabhakar, U., Lang, Z., Corringham, R. E., Beckman, R. A., and Jayson, G. C. (2007) Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res. 13, 2128-2135. (Pubitemid 46649882)
37. Brooks, P. C., Klemke, R. L., Schon, S., Lewis, J. M., Schwartz, M. A., and Cheresh, D. A. (1997) Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J. Clin. Invest. 99, 1390-1398. (Pubitemid 27142777)
38. Stupp, R., and Ruegg, C. (2007) Integrin inhibitors reaching the clinic. J. Clin. Oncol. 25, 1637-1638. (Pubitemid 46797938)
39. Hariharan, S., Gustafson, D., Holden, S., McConkey, D., Davis, D., Morrow, M., Basche, M., Gore, L., Zang, C., O'Bryant, C. L., Baron, A., Gallemann, D., Colevas, D., and Eckhardt, S. G. (2007) Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann. Oncol. 18, 1400-1407. (Pubitemid 47305015)
40. Friess, H., Langrehr, J. M., Oettle, H., Raedle, J., Niedergethmann, M., Dittrich, C., Hossfeld, D. K., Stoger, H., Neyns, B., Herzog, P., Piedbois, P., Dobrowolski, F., Scheithauer, W., Hawkins, R., Katz, F., Balcke, P., Vermorken, J., van Belle, S., Davidson, N., Esteve, A. A., Castellano, D., Kleeff, J., Tempia-Caliera, A. A., Kovar, A., and Nippgen, J. (2006) A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6, 285.
41. Ramakrishnan, V., Bhaskar, V., Law, D. A., Wong, M. H., DuBridge, R. B., Breinberg, D., O'Hara, C., Powers, D. B., Liu, G., Grove, J., Hevezi, P., Cass, K. M., Watson, S., Evangelista, F., Powers, R. A., Finck, B., Wills, M., Caras, I., Fang, Y., McDonald, D., Johnson, D., Murray, R., and Jeffry, U. (2006) Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J. Exp. Ther. Oncol. 5, 273-286. (Pubitemid 44497002)
42. Kuwada, S. K. (2007) Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr. Opin. Mol. Ther. 9, 92-98. (Pubitemid 46438452)
43. Ma, W. W., and Adjei, A. A. (2009) Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 59, 111-137.
44. Stoeltzing, O., Liu, W., Reinmuth, N., Fan, F., Parry, G. C., Parikh, A. A., McCarty, M. F., Bucana, C. D., Mazar, A. P., and Ellis, L. M. (2003) Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer. 104, 496-503. (Pubitemid 36323922)